Beijing Science Sun Pharmaceutical (300485.SZ) subsidiary withdraws a drug registration application.

16:15 20/03/2026

Sai Sheng Pharmaceutical (300485.SZ) announced that its subsidiary, Beijing Sai Er Biological Pharmaceutical Co., Ltd. (referred to as "Sai Er Biological"), recently received a "Notice of Termination of Drug Registration Application" issued by the National Medical Products Administration, approving Sai Er Biological to withdraw the registration application for Dapagliflozin tablets.

Beijing Science Sun Pharmaceutical (300485.SZ) announced that its subsidiary, Beijing Science Biological Pharmaceutical Co., Ltd. (referred to as "Science Biological"), recently received a "Medicine Registration Application Termination Notice" issued by the National Medical Products Administration, agreeing to withdraw its application for the registration of Dapagliflozin tablets. The announcement stated that Science Biological submitted an application for the market approval of Dapagliflozin tablets to the National Medical Products Administration in March 2025 and was accepted. Due to changes in policies and regulations and other factors, further improvement of application materials is needed. Therefore, they have voluntarily withdrawn this application.

HENLIUS (02696)Naluriyou monoclonal anti-drug similar to drug HLX18 (recombinant humanized monoclonal antibody injection) for the treatment of various solid tumors has received approval from the National Medical Products Administration for phase 1 clinical trial application.

Chengdu Wintrue Holding (002539.SZ): 700,000 tons of synthetic ammonia project completed trial production.

ONEWO (02602) spent approximately HKD 4.7346 million on March 20 to repurchase 270,000 shares.

Chengdu Wintrue Holding (002539.SZ): 700,000 tons of synthetic ammonia project completed trial production.

ONEWO (02602) spent approximately HKD 4.7346 million on March 20 to repurchase 270,000 shares.